Innovation Birmingham-based 15-year-old digital tech entrepreneur Kari Lawler is set to pitch in front of UK Space Agency heads in June after winning the UK Space SatelLife Challenge 2018.
The Challenge was launched by the UK Space Agency, offering the chance for 11-22-year-olds to get expert advice around their ideas on how satellites can improve life on Earth.
Manchester Science Partnerships (MSP) has launched a new £2m tech incubator that will result in up to 2,000 jobs being created in data science and technology innovation companies over the next ten years.
The incubator, supported by a £2m award from Manchester City Council, will provide start-ups with a wide package of business support services and is designed for start-ups working in areas such as artifical intelligence, data analytics, cyber security, cloud technologies and digital health.
Global software as a service developer, Eight Technology (with its Dealerweb Showroom and React platforms) is the first company to have signed to move into the grow-on buildings at Exeter Science Park to accommodate its expanding team.
Boasting almost a thousand years of history, Warwick Castle has collaborated with Innovation Birmingham-based production company CMA Video to deliver a modern-day celebration of the medieval site’s 950th anniversary.
Exactly 950 individual pictures were combined to form a one-off portrait mosaic in April to honour William the Conqueror, who built the original castle in 1068.
Engine Shed has announced the appointment of Briony Phillips as Associate Director. Briony has been part of Engine Shed’s team since May 2017 as the organisation’s Scale Up Enabler. The new position will continue to focus on development of the scale up ecosystem and support of the Growth Hub, with part funding of the role by WECA for this purpose.
TC BioPharm Ltd (TCB) and Scotia Biologics announced today that they have formed a strategic collaboration to co-develop novel proprietary tumour-specific antibodies for TCB’s CAR-T platform. Using Scotia’s unique, proven technology, the two companies will develop a range of cancer-targeting single-chain antibodies, each of which can be formulated to treat a specific type of cancer. Antibodies developed by Scotia will be incorporated into TCB’s therapeutic ImmuniCAR® product range.